Oncology

SUDOSCAN in Oncology : Chemotherapy Induced Polyneuropathy

Oncology, Scientific publications / By Impeto Medical

SUDOSCAN in Oncology : Chemotherapy InduCed Polyneuropathy Two studies evaluating SUDOSCAN Severe drug-induced neurotoxic adverse effects constitute the second most common cause of dose limitation after haematological adverse effects. Chemotherapy Induced Polyneuropathy (CIPN) is commonly associated with platinum analogues, antitubulins (taxane), the proteasome inhibitor bortezomib, and thalidomide. However, it is poorly investigated at an early …

SUDOSCAN in Oncology : Chemotherapy Induced Polyneuropathy Read More »

Promotional Communication. The medical devices SUDOSCAN & EZSCAN are regulated health products under the CE certification, Class IIa, according to the European Medical Device directive – SGS Belgium, notified body 1639. The test allows screening and monitoring of peripheral autonomic neuropathies. It can be performed in diabetic patients or in patients suffering from neurological diseases involving small fibers damage. As with any diagnostic test, its results must be interpreted in a global context including the clinic and other examinations performed. Please read the user manual instructions carefully. Contact our office for more information. Last update: 2021/01/12

SUDOSCAN in Oncology : Chemotherapy Induced Polyneuropathy

ABOUT US:

MORE INFORMATION:

IMPETO MEDICAL WORLD:

FOLLOW US ON:

CONTACT INFO: